About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol

By: via GlobeNewswire
  • Gildeuretinol acetate demonstrated less loss in ellipsoid zone (EZ) area compared to historical sibling controls.
  • Early-stage Stargardt disease patients treated with gildeuretinol for two to seven years exhibited relatively stable disease over the course therapy.
  • Gildeuretinol was well tolerated and had a safety profile consistent with prior gildeuretinol studies, with the majority of adverse events being mild or moderate.

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced the presentation of an interim data update from its TEASE-3 study demonstrating that five early-stage Stargardt disease patients treated with investigational oral gildeuretinol acetate experienced less loss in ellipsoid zone (EZ) area compared to historical sibling controls and overall disease remained relatively stable while on therapy ranging between two to seven years. The study update was presented during the 43rd American Society of Retina Specialists (ASRS) Annual Scientific Meeting, held July 30 – Aug. 2 in Long Beach, Calif.

“We are encouraged by this new interim data from the TEASE-3 study of gildeuretinol in early-stage Stargardt patients with confirmed disease-causing ABCA4 genetic mutations,” said Seemi Khan, M.D., M.P.H., M.B.A., Chief Medical Officer of Alkeus Pharmaceuticals. “These additional data further support the potential of investigational gildeuretinol to slow disease progression and stabilize vision in individuals living with Stargardt disease. We are excited to continue advancing our efforts towards delivering a treatment for Stargardt disease.”

TEASE-3, the first clinical trial in early-stage Stargardt disease, is an open-label study of gildeuretinol in genetically confirmed patients who exhibit early retinal changes on imaging but have not yet developed meaningful symptoms of vision loss. TEASE-3 study participants each have a sibling who was previously diagnosed with Stargardt disease.

The disease progression over two years is assessed by retinal imaging and functional outcome measures. After the initial two-year treatment period, patients continue to receive gildeuretinol while enrolled in an open label long-term extension study. In the TEASE-3 study, five patients have completed two years of treatment with once-daily oral gildeuretinol.

Gildeuretinol was well tolerated and demonstrated a safety profile consistent with prior gildeuretinol studies, with the majority of adverse events being mild or moderate in severity.

“Time is of the essence for patients losing vision from early-onset Stargardt disease,” said Kenneth Fan, M.D., M.B.A., Retina Consultants of Texas. “With no approved treatments available, these data inform our understanding of retinal health in early-stage disease and underscore the importance of ongoing clinical evaluation.”

About Stargardt Disease

Stargardt disease is a serious cause of blindness in children and adults, with an estimated 30,000 people affected in the U.S. and more than 150,000 worldwide. There is no approved treatment. In individuals with Stargardt disease, the ABCA4 protein is defective. This defect in the protein results in the accelerated dimerization of vitamin A, forming toxic by-products that irreversibly damage the retina, resulting in progressive vision loss.

About Alkeus Pharmaceuticals

Alkeus Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Based in Cambridge, Mass., Alkeus is backed by institutional investors led by Bain Capital Life Sciences. Alkeus is developing therapies for serious diseases of the eye with high unmet need. Alkeus’ breakthrough-designated lead candidate, oral gildeuretinol acetate (ALK-001), is being evaluated in clinical trials for the treatment of Stargardt disease and for geographic atrophy secondary to age-related macular degeneration.

About Gildeuretinol Acetate (ALK-001)

Oral gildeuretinol acetate (ALK-001) is a new molecular entity designed to reduce the dimerization of vitamin A without modulating the visual cycle. Gildeuretinol is being evaluated in clinical trials for the treatment of Stargardt disease and for geographic atrophy secondary to age-related macular degeneration. Gildeuretinol has received Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for Stargardt disease from the U.S. Food and Drug Administration.

About the TEASE Program

The Tolerability and Effects of ALK-001 on Stargardt diseasE (TEASE) studies consist of four independent clinical studies of oral gildeuretinol acetate (ALK-001) in Stargardt disease, denoted as TEASE-1, TEASE-2, TEASE-3 and TEASE-4. The TEASE-1 study was a randomized, double-masked, placebo-controlled trial in 50 patients with advanced Stargardt disease and is complete. The TEASE-2 trial is a randomized, double-masked, placebo-controlled trial in 80 patients with moderate Stargardt disease, expected to read out topline data in 2025. TEASE-3, a clinical trial in early-stage Stargardt disease, is an ongoing open-label study of gildeuretinol in genetically confirmed patients with early signs of disease visible on retinal imaging, but who have not begun experiencing meaningful symptoms of vision loss. TEASE-4 is an ongoing open-label extension study.

For further information, please contact:

Media Relations
Media@alkeuspharma.com
Website: www.alkeuspharma.com


Primary Logo

More News

View More
Pure Storage Hits New High: AI’s Under-the-Radar Powerhouse
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWD IT MSFT PSTG
MP Materials' New Role as a Strategic U.S. Asset
Via MarketBeat
Topics Economy Government
Tickers AAPL MP
3 Healthcare Companies Insiders Are Buying
Via MarketBeat
Topics Initial Public Offering
Tickers CAMP LLY SI
Analyst Downgrades Hit Homebuilders—But Opportunity Looms
Via MarketBeat
Topics World Trade
Tickers LEN PHM
3 Defensive Stocks to Buy as Economic Uncertainty Lingers
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CLX COST CVX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.